At DCAT Week 2022, Graham Lewis, IQVIA, provided a market outlook for the global bio/pharma industry: the growth opportunities and challenges. What is projected for the near term?
After a robust 2021, the CDMO industry entered 2022 with a lot of momentum, but at the close of 1Q 2022, market conditions are more uncertain. Highlights from a DCAT Week 2022 presentation.
Executives Outline Expansion Plans at the DCAT Member Company Announcement Forum
CEOs and senior executives from DCAT Member Companies provided the latest major news from their companies across the bio/pharmaceutical manufacturing value chain at the DCAT Member Company Forum at DCAT Week 2022.
Incorporating Sustainability into the Bio/Pharma Supply Chain: Where Does the Industry Stand?
A newly released DCAT benchmarking study examines the targets and progress made by bio/pharma companies and suppliers in reaching their sustainability goals.
The Pharma Pulse: The FDA, Mfg, and Quality Metrics
The FDA is seeking industry input on a redirection of its proposed Quality Metrics Program and its reporting requirements for drug manufacturers–both bio/pharma companies and CDMOs. What’s in the new plan?
Capital investments are ramping up in biomanufacturing, which continues to be an active area for CDMOs/CMOs in both traditional biologics and new modalities. Which companies are expanding?
A DCAT Week program brings together leading Bio/Pharma executives to offer their perspectives on how Bio/Pharma companies and their suppliers are adjusting supply practices now and in the near term.
In a special program at DCAT Week, Aamir Malik, Executive Vice President and Chief Business Innovation Officer, Pfizer, provides industry reflections on the drivers and key trends in new drug development.
How will digital technologies, such as AI, blockchain, and predictive analytics, change the way business is conducted between Bio/Pharma companies and suppliers? A DCAT Week program has the answers.
Will 2022 be a good year for the global Bio/Pharma industry? What factors are impacting growth? And how will the CDMO/CMO sector fare? A DCAT Week program provides an outlook for 2022 and near term.
